Viatris reports Q4 adjusted EPS 54c, consensus 57c

Reports Q4 revenue $3.52B, consensus $3.6B. “2024 was a good year for Viatris (VTRS) with full year operational revenue growth of 2%, excluding divestitures, in line with our guidance,” said Scott Smith, CEO, Viatris. “As we head into 2025, we are focused on driving strong commercial execution, advancing our pipeline-including several important late-stage development milestones for selatogrel, cenerimod and sotagliflozin and six Phase 3 readouts-prioritizing capital return with a focus on share repurchases, executing our remediation plan for Indore and beginning an enterprise-wide initiative to review our global infrastructure and identify additional cost savings.”